Advanced search
Publication Cover
Therapeutic Delivery Volume 3, 2012 - Issue 5
Submit an article Journal homepage
198
Views
0
CrossRef citations to date
0
Altmetric
Perspective

Drug Delivery Via lipoprotein-based Carriers: Answering the Challenges in Systemic Therapeutics

Nirupama Sabnisa Department of Molecular Biology & Immunology UNT Health Science Center3500 Camp Bowie BlvdFort WorthTX76107USA
&
Andras G Lackob Department of Molecular Biology & Immunology UNT Health Science Center3500 Camp Bowie BlvdFort [email protected]
Pages 599-608 | Published online: 17 May 2012

References

  • Petkar KC , ChavhanSS, Agatonovik-KustrinS, SawantKK. Nanostructured materials in drug and gene delivery: a review of the state of the art. Crit. Rev. Ther. Drug Carrier Syst.28(2), 101–164 (2011).
  • Chakraborty M , JainS and Rani V. Nanotechnology: emerging tool for diagnostics and therapeutics. Appl. Biochem. Biotechnol.165(5–6), 1178–1187 (2011).
  • Ma X , ZhaoY, LiangXJ. Theranostic nanoparticles engineered for clinic and pharmaceutics. Acc. Chem. Res.44(10), 1114–1122 (2011).
  • De Jong WH , BormPJ. Drug delivery and nanoparticles: applications and hazards. Int. J. Nanomed.3(2), 133–149 (2008).
  • Ward CS , VenkateshHS, ChaumeilMMet al. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res. 70(4), 1296–1305 (2010).
  • Lewis DR , KamisogluK, YorkAW, MoghePV. Polymer-based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosis. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.3(4), 400–420 (2011).
  • Chekman IS , UlbergZR, GorchakovaNOet al. The prospects of medical application of metal-basednanoparticles and nanomaterials. Lik. Sprava. 1–2, 3–21 (2011).
  • Kaminskas LM , PorterCJ. Targeting the lymphatics using dendritic polymers (dendrimers). Adv. Drug Deliv. Rev.63(10–11), 890–900 (2011).
  • Chen F , ZhuYJ, ZhangKHet al. Europium-doped amorphous calcium phosphate porous nanospheres: preparation and application as luminescent drug carriers. Nanoscale Res. Lett. 6(1), 67 (2011).
  • Liu H , WebsterTJ. Mechanical properties of dispersed ceramic nanoparticles in polymer composites for orthopedic applications. Int. J. Nanomed.5, 299–313 (2010).
  • Waiczies H , LeporeS, JanitzekNet al. Perfluorocarbon particle size influences magnetic resonance signal and immunological properties of dendritic cells. PLoS One 6(7), 21981–21990 (2011).
  • Kempe M , KempeH, SnowballIet al. The use of magnetite nanoparticles for implant-assisted magnetic drug targeting in thrombolytic therapy. Biomaterials 31(36), 9499–9510 (2010).
  • Maysinger D , LovricJ. Quantum dots and other fluorescent nanoparticles: quo vadis in the cell? Adv. Exp. Med. Biol.620, 156–167 (2007).
  • Lacko AG , NairM, ProkaiL, McConathyWJ. Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. Exp. Opin. Drug Deliv.4(6), 665–675 (2007).
  • Ng KK , LovellJF, ZhengG. Lipoprotein-inspired nanoparticles for cancer theranostics. Acc. Chem. Res.44(10), 1105–1113 (2011).
  • Elnaggar YS , El-MassikMA, AbdallahOY. Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipidnanoparticles. Int. J. Nanomed.6, 3195–3205 (2011).
  • Wang JJ , ZengZW, XiaoRZet al. Recent advances of chitosannanoparticles as drug carriers. Int. J. Nanomed. 6, 765–774 (2011).
  • Spuch C , NavarroC. Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer‘s disease and Parkinson‘s disease). J. Drug Deliv. doi:10.1155/2011/469679 (2011).
  • Attama AA . SLN, NLC, LDC: state of the art in drug and active delivery. Recent Pat. Drug Deliv. Formul.5(3), 178–187 (2011).
  • Shahzad MM , MangalaLS, HanHDet al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 13(4), 309–319 (2011).
  • Zheng G , ChenJ, LiH, GlicksonJD. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc. Natl Acad. Sci. USA102(49), 17757–17762 (2005).
  • Mooberry LK , NairM, ParanjapeS, McConathyWJ, LackoAG. Receptor-mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J. Drug Target.18(1), 53–58 (2010).
  • Sabnis N , NairM, IsraelM, WalterJ, McConathyWJ, LackoAG. Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. Int. J. Nanomed.7, 1–9 (2012).
  • McConathy WJ , NairMP, ParanjapeS, MooberryL, LackoAG. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs19(2), 183–188 (2008).
  • Gotto AM , PownallHJ, HavelRJ. Introduction to the plasma lipoproteins. Methods Enzymol.128, 3–41 (1986).
  • Chapman MJ . Animal lipoproteins: chemistry, structure, and comparative aspects. J. Lipid Res.21(7), 789–853 (1980).
  • Bricarello DA , SmilowitzJT, ZivkovicAM, GermanJB, ParikhAN. Reconstituted lipoprotein: a versatile class of biologically-inspired nanostructures. ACS Nano.5(1), 42–57 (2011).
  • Pluen A , BoucherY, RamanujanSet al. Role of tumor host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc. Natl Acad. Sci. USA 98(8), 4628–4633 (2001).
  • Thomas M , BhatS, Sorci-ThomasM. Three-dimensional models of HDL APOA-I. Implications for its assembly and function. J. Lipid Res.49(9), 1875–1883 (2008).
  • Denisov I , GrinkovaY, LazaridesA, SligarS. Directed self-assembly of monodisperse phospholipid bilayer nanodiscs with controlled size. J. Am. Chem. Soc.126(11), 3477–3487 (2004).
  • Chen J , CorbinIR, LiH, CaoW, GlicksonJD, ZhengG. Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo. J. Am. Chem. Soc.129(18), 5798–5798 (2007).
  • Tatarczyk T , CiardiC, NiederwangerA, KranebitterM, PatschJR, PedriniMT. Postprandial triglyceride-rich lipoproteins induce hepatic insulin resistance in HepG2 cells independently of their receptor-mediated cellular uptake. Mol. Cell Endocrinol.343(1–2), 71–78 (2011).
  • McConathy WJ , ParanjapeS, MooberryLet al. Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF). Drug Deliv. Transl. Res. 1(2), 113–120 (2011).
  • Krieger M , SmithLC, AndersonRGet al. Reconstituted low density lipoprotein: a vehicle for the delivery of hydrophobic fluorescent probes to cells. J. Supramol. Struct. 10(4), 467–478 (1979).
  • Gal D , MacdonaldPC, PorterJC, SimpsonER. Cholesterol metabolism in cancer cells in monolayer culture. III. Low-density lipoprotein metabolism. Int. J. Cancer28(3), 315–319 (1981).
  • Kader A , PaterAJ. Loading anticancer drugs into HDL as well as LDL has little effect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J. Control. Rel.80(1–3), 29–44 (2002).
  • Ponty E , FavreG, BenanibaRet al. Biodistribution study of 99mTc-labeled LDL in B16-melanoma-bearing mice: visualization of a preferential uptake by the tumor. Int. J. Cancer 54(11), 411–417 (1993).
  • Corbin IR , LiH, ChenJet al. Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. Neoplasia 8(6), 488–498 (2006).
  • De Smidt PC , Van Berkel TJ. LDL-mediated drug targeting. Crit. Rev. Ther. Drug Carrier Syst.7(2), 99–120(1990).
  • Vitols S , AngelinB, EricssonSet al. Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proc. Natl Acad. Sci. USA 87(7), 2598–2602 (1990).
  • Dorlhiac-Llacer PE , MarqueziniMV, ToffolettoO, CarneiroRC, MaranhãoRC, ChamoneDA. In vitro cytotoxicity of the LDE: daunorubicin complex in acute myelogenous leukemia blast cells. Braz. J. Med. Biol. Res.34(10), 1257–1263 (2001).
  • Ahotupa M , SuomelaJP, VuorimaaT, VasankariT. Lipoprotein-specific transport of circulating lipid peroxides. Annu. Med.42(7), 521–529 (2010).
  • Meng QH , WähäläK, AdlercreutzH, TikkanenMJ. Antiproliferative efficacy of lipophilic soy isoflavone phytoestrogens delivered by low density lipoprotein particles into cultured U937 cells. Life Sci.65(16), 1695–1705 (1999).
  • Lestavel-Delattre S , Martin-NizardF, ClaveyVet al. Low-density lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells. Cancer Res. 52(13), 3629–3635 (1992).
  • Hu J , LiuH, WangL. Enhanced delivery of AZT to macrophages via acetylated LDL. J. Control. Rel.69(3), 327–335 (2000).
  • Jin H , LovellJF, ChenJet al. Cytosolic delivery of LDL nanoparticle cargo using photochemical internalization. Photochem. Photobiol. Sci. 10(5), 810–816 (2011).
  • Crich SG , LanzardoS, AlbertiDet al. Magnetic resonance imaging detection of tumor cells by targeting low-density lipoprotein receptors with Gd-loaded low-density lipoprotein particles. Neoplasia 9(12), 1046–1056 (2007).
  • Owens MD , BaillieG, HalbertGW. Physicochemical properties of microemulsion analogues of low density lipoprotein containing amphiphatic apoprotein B receptor sequences. Int. J. Pharm.228(1–2), 109–117 (2001).
  • Shaw JM , ShawKV. Key issues in the delivery of pharmacological agents using lipoproteins: design of a synthetic apoprotein–lipid carrier. Target. Diagn. Ther.5, 351–383 (1991).
  • de Smidt PC , VersluisAJ, van Berkel TJ. Properties of incorporation, redistribution, and integrity of porphyrin-low-density lipoprotein complexes. Biochemistry32(11), 2916–2922 (1993).
  • Masquelier M , VitolsS, PalssonM, MarsU, LarssonBS, PetersonC. Low density lipoprotein as a carrier of cytostatics in cancer chemotherapy: study of stability of drug-carrier complexes in blood. J. Drug Target.8(3), 155–164 (2000).
  • Clayman RV , BilhartzLE, SpadyDK, BujaLM, DietschyJM. Low density lipoprotein-receptor activity is lost in vivo in malignantly transformed renal tissue. FEBS Lett.196(1), 87–90 (1986).
  • Fabricant M , BroitmanSA. Evidence for deficiency of low density lipoprotein receptor on human colonic carcinoma cell lines. Cancer Res.50(3), 632–636 (1990).
  • Tatidis L , MasquelierM, VitolsS. Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines. Biochem. Pharmacol.63(12), 2169–2180 (2002).
  • Glomset JA . The plasma lecithins: cholesterol acyltransferase reaction. J. Lipid Res.9(2), 155–167 (1968).
  • Acton S , RigottiA, LandschulzKT, XuS, HobbsHH, KriegerM. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science271(5248), 518–520 (1996).
  • Leon CG , LockeJA, AdomatHHet al. Alterations in cholesterol regulation contribute to the production of intra tumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 70(4), 390–400 (2010).
  • Kader A , PaterAJ. Loading anticancer drugs into HDL as well as LDL has little effect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J. Control. Rel.80(1–3), 29–44 (2002).
  • Lou B , LiaoXL, WuMP, ChengPF, YinCY, FeiZ. High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. World J. Gastroenterol.11(7), 954–959 (2005).
  • Zhang WL , XiaoY, LiuJPet al. Structure and remodeling behavior of drug-loaded high density lipoproteins and their atherosclerotic plaque targeting mechanism in foam cell model. Int. J. Pharm. 419(1–2), 314–321 (2011).
  • Cho KH . Enhanced delivery of rapamycin by V156K-ApoA-I high-density lipoprotein inhibits cellular proatherogenic effects and senescence and promotes tissue regeneration. J. Gerontol. A Biol. Sci. Med. Sci.66(12), 1274–1285 (2011).
  • Shiflett AM , BishopJR, PahwaA, HajdukSL. Human high density lipoproteins are platforms for the assembly of multicomponent innate immune complexes. J. Biol. Chem.280, 32578–32585 (2005).
  • Feng M , CaiQ, ShiXet al. Recombinant high-density lipoprotein complex as a targeting system of nosiheptide to liver cells. J. Drug Target. 16(6), 502–508 (2008).
  • Bhattacharya P , GrimmeS, GaneshBet al. Nanodisc-incorporated hemagglutinin provides protective immunity against influenza virus infection. J. Virol. 84, 361–371 (2010).
  • de Vrueh RL , RumpET, van De Bilt E et al. Carrier-mediated delivery of 9-(2-phosphonylmethoxyethyl) adenine to parenchymal liver cells: a novel therapeutic approach for hepatitis B. Antimicrob. Agents Chemother.44(3), 477–483 (2000).
  • Nelson K , BishopJ, RyanR, TitusR. Nanodisk-associated amphotericin B clears leishmania major cutaneous infection in susceptible balb/c mice. Antimicrob. Agents Chemother.50(4), 1238–1244 (2006).
  • Handattu S , GarberD, MonroeCet al. Oral apolipoprotein AI mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer‘s disease. Neurobiol. Dis. 34(3), 525–534 (2009).
  • Paula-Lima AC , TricerriMA, Brito-MoreiraJet al. Human apolipoprotein A-I binds amyloid-[β] and prevents a[β]-induced neurotoxicity. Int. J. Biochem. Cell Biol. 41, 1361–1370 (2009).
  • Balazs Z , PanzenboeckU, HammerAet al. Uptake and transport of high density lipoprotein (HDL) and HDL associated tocopherol by an in vitro blood–brain barrier model. J. Neurochem. 89(4), 939–950 (2004).
  • Paternò R , RuoccoA, PostiglioneA, HubschA, AndresenI, LangMG. Reconstituted high-density lipoprotein exhibits neuroprotection in two rat models of stroke. Cerebrovasc. Dis.17(2–3), 204–211 (2004).
  • Lapergue B , MorenoJA, DangBQet al. Protective effect of high-density lipoprotein-based therapy in a model of embolic stroke. Stroke 41(7), 1536–1542 (2010).
  • Drew BG , DuffySJ, FormosaMFet al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119, 2103–2111 (2009).
  • Drew BG , CareyAL, NatoliAKet al. Reconstituted high-density lipoprotein infusion modulates fatty acid metabolism in patients with type 2 diabetes mellitus. J. Lipid Res. 52(3), 572–581 (2011).
  • Calkin AC , DrewBG, OnoAet al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 120, 2095–2104 (2009).
  • Ryan RO , ForteTM, OdaMN. Optimized bacterial expression of human apolipoprotein A-I. Protein Expr. Purif.27(1), 98–103 (2003).
  • Banerjee S , HuberT, SakmarTP. Rapidincorporationof functionalrhodopsin into nanoscale apolipoprotein bound bilayer (NABB) particles. J. Mol Biol.377(4), 1067–1081 (2008).
  • Hovingh GK , BochemAE, KasteleinJJ. Apolipoprotein A-I mimetic peptides. Curr. Opin. Lipidol.21(6), 481–486 (2010).
  • Yang M , ChenJ, CaoWet al. Attenuation of nontargeted cell-kill using a high-density lipoprotein-mimicking peptide–phospholipid nanoscaffold. Nanomedicine (Lond.) 6(4), 631–641 (2011).
  • Anantharamaiah GM , JonesJL, BrouilletteCGet al. Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J. Biol. Chem. 260(18), 10248–10255 (1985).
  • Zhang Z , ChenJ, DingLet al. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small 6(3), 430–437 (2010).
  • Counsell RE , PohlandRC. Lipoproteins as potential site-specific delivery systems for diagnostic and therapeutic agents. J. Med. Chem.25(10), 111–125 (1982).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.